This study makes the important observation that tumors from patients with BRCA2 mutations had increased PD‐L1 mRNA expression and a higher percentage of PD‐L1 protein expression in tumor‐associated ICs compared to patients with BRCA1 mutations. This evidence concerns the gene BRCA2 and neoplasm.